Trade PTC Therapeutics Inc - PTCT CFD

Trading Conditions

• TypeThis financial instrument is available for trading through CFDs and Knock-outs.Knock-out options available only for selected countries.Learn more about:CFDsKnock-outs:
  CFD

  

  Knock-out

  
• Spread: 0.13
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021485 %(-$0.43)Trade size with leverage ~ $2,000.00Money from leverage ~$1,000.00Go to platform: -0.02149%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000738 %(-$0.01)Trade size with leverage ~ $2,000.00Money from leverage ~$1,000.00Go to platform: -0.00074%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021485 %
  (-$0.43)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000738 %
  (-$0.01)

Key Stats

• Prev. Close: 71.91
• Open: 70.8
• 1-Year Change: 46.95%
• Day's Range: 70.8 - 71.88

Trade PTC Therapeutics Inc - PTCT

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, PTC Therapeutics, Inc. revenues increased 41% to $538.6M. Net loss increased 20% to $523.9M. Revenues reflect United States segment increase of 59% to $297M, Non-US segment increase of 24% to $241.6M. Higher net loss reflects Non-GAAP research and development increase of 11% to $487.1M (expense), Interest expense, net - Balancing value increase of 52% to $85.1M (expense).

Equity composition

Common Stock $0.001 Par, Shares auth 125M., 22,206,190 shares issd,. Insiders Owns approx.68.93%